Immunovant, Inc. (IMVT): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMVT Stock Price Chart Interactive Chart >
IMVT Price/Volume Stats
| Current price | $4.30 | 52-week high | $10.98 |
| Prev. close | $4.07 | 52-week low | $3.14 |
| Day low | $4.07 | Volume | 78,440 |
| Day high | $4.36 | Avg. volume | 534,077 |
| 50-day MA | $4.07 | Dividend yield | N/A |
| 200-day MA | $6.35 | Market Cap | 501.02M |
Immunovant, Inc. (IMVT) Company Bio
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest IMVT News From Around the Web
Below are the latest news stories about Immunovant Inc that investors may wish to consider to help them evaluate IMVT as an investment opportunity.
Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT)There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Immunovant (IMVT – Research Report) with bullish sentiments. Immunovant (IMVT) In a report issued on February 4, Thomas Smith from Leerink Partners maintained a Buy rating on Immunovant, with a price target of $12.00. The company's shares closed last Thursday at $5.58, close to its 52-week low of $5.46. According to TipRanks. |
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceNEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022. |
H.C. Wainwright Thinks Immunovant’s Stock is Going to RecoverIn a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Immunovant (IMVT – Research Report), with a price target of $16.00. The company's shares closed last Friday at $5.91, close to its 52-week low of $5.69. According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.9% and a 38.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines. Immunovant has an analyst consensus of Strong Buy, with a price target consensus of $14.25. See Insiders’ Hot Stocks on TipRanks >> Immunovant's market cap is currently $679. |
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3Immunovant's (IMVT) earnings miss estimates in fiscal third-quarter, which ended on Dec 31, 2021. Focus remains on lead pipeline candidate batoclimab. |
Immunovant GAAP EPS of -$0.36 misses by $0.04Immunovant press release (IMVT): Q3 GAAP EPS of -$0.36 misses by $0.04.Cash balance of $527M (as of Dec |
IMVT Price Returns
| 1-mo | 0.70% |
| 3-mo | -14.68% |
| 6-mo | -46.18% |
| 1-year | -59.51% |
| 3-year | -56.03% |
| 5-year | N/A |
| YTD | -49.53% |
| 2021 | -81.55% |
| 2020 | 191.05% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...